Nouscom Poster presentation at SITC 2021

Nouscom Poster presentation at SITC 2021, reporting interim Phase 1 results on Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI). Data from 12 metastatic MSI-H GI patients continues to demonstrate a favorable safety profile, high levels of vaccine immunogenicity and exctiting early evidence of clinical efficacy highlighting the potential of NOUS-209.

• Overman M.J. al., SITC 2021 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI)